Plus Therapeutics Commences Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial (Investing.com) - Mar 22, 2023 - "Plus Therapeutics...announced treatment of the first patient in Cohort 3 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors."
Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|